TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection shows promise in slowing devastating nerve disease
Disease control CompletedThis study tested whether a new drug called vutrisiran could help people with hereditary transthyretin amyloidosis (hATTR), a rare disease where a faulty protein builds up and damages nerves and organs. 164 patients received injections of either vutrisiran or an existing treatmen…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists hunt for early warning signs of a silent killer
Knowledge-focused CompletedThis study aimed to understand how a serious inherited disease called hereditary transthyretin amyloidosis begins. Researchers followed 37 people who carry the disease gene but had no symptoms, tracking a specific protein in their blood over five years. The goal was to see if thi…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC